CA-POSIFLEX
5.1.2022 18:02:06 CET | Business Wire | Press release
Posiflex is pleased to join National Retail Federation’s Big Show for 2022 and will be showcasing its latest point-of-sale solutions in booth #5919. After a two-year-long hiatus from a live NRF show, anticipation is at an all-time high, and Posiflex is excited to exhibit its full line of point-of-sale (POS) terminals, kiosks, tablets and more—along with a few surprises—optimized for retailers in search of powerful and flexible post-pandemic solutions for their operations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220105005004/en/
In addition, Posiflex will showcase a new line of POS terminals for today’s retail demands, including the versatile XT7315 , and exciting, fresh models from the new RT6000 Series: the RT6015 and RT6016 .
The XT7315 comes with a wide selection of processors that can suit virtually any point-of-sale requirement. Running on Windows 10 IoT Enterprise OS platform, the XT7315 is housed in a stylish, durable exterior and has a well-designed base that allows for optimal cable management. With its choice of processors, plus a multi-position folding base and a fanless design, the XT7315 continues the excellence of quality and performance that the line of Posiflex XT Series is well-known for.
The new RT6000 Series includes two models: the RT6015 and RT6016, both providing a selection of Intel processors geared for maximum performance and uptime. The main difference between the two models is the display size, with the RT6015 having a 15”/4:3 standard-ratio touch screen display and the RT6016 having a 15.6”/16:9 widescreen-ratio touch screen display. Running on Windows 10 IoT Enterprise and sporting the same exceptional characteristics from the RT Series family, including sleek aesthetics, durability, performance, and reliability, the Posiflex RT6000 Series is an ideal fit for Retail, Hospitality or Specialty-Service establishments.
“With rigorous HALT/HASS testing and total in-house manufacturing that all our products experience, our new XT7315 and RT6000 terminals extend the Posiflex legacy of providing top-notch point-of-sale hardware for today’s challenging atmosphere and customers’ demands,” says Doyle Ledford, VP of Sales & Marketing for Posiflex. “We look forward to introducing these exceptional products along with the rest of our latest solutions at NRF 2022.”
About Posiflex
Since 1984, Posiflex has designed and manufactured award-winning POS terminals and peripherals. Posiflex has since grown exponentially to provide not only full-service POS stations, but also versatile self-service kiosks, state-of-the-art mobile tablets, and scalable embedded PC solutions. Renowned worldwide in the retail and hospitality industries, Posiflex is a proven leader in POS hardware for Windows and Android OS. More than 30 patents and numerous awards have been won for product innovation, design, and reliability. https://www.posiflexusa.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005004/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom